Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Analysts at Oppenheimer Holdings decreased their Q3 2018 earnings per share estimates for Vanda Pharmaceuticals in a research report issued on Sunday. Oppenheimer Holdings analyst D. Archila now forecasts that the biopharmaceutical company will post earnings per share of $0.00 for the quarter, down from their prior forecast of $0.01. Oppenheimer Holdings currently has a “Buy” rating and a $25.00 target price on the stock. Oppenheimer Holdings also issued estimates for Vanda Pharmaceuticals’ Q4 2018 earnings at $0.04 EPS.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.10). Vanda Pharmaceuticals had a negative return on equity of 10.99% and a negative net margin of 9.01%. The firm had revenue of $41.30 million during the quarter, compared to analyst estimates of $43.90 million. During the same period in the prior year, the company posted ($0.01) earnings per share. The business’s revenue for the quarter was up 7.3% compared to the same quarter last year.

TRADEMARK VIOLATION NOTICE: This article was published by Watch List News and is the property of of Watch List News. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.watchlistnews.com/equities-analysts-issue-forecasts-for-vanda-pharmaceuticals-inc-s-q3-2018-earnings-vnda/1707831.html.

A number of other analysts have also weighed in on the company. Zacks Investment Research lowered Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, October 26th. Jefferies Group LLC reiterated a “buy” rating and issued a $21.00 price objective on shares of Vanda Pharmaceuticals in a research report on Tuesday, August 29th. Piper Jaffray Companies lifted their price objective on Vanda Pharmaceuticals from $23.00 to $26.00 and gave the stock an “overweight” rating in a research report on Thursday, September 14th. BidaskClub upgraded Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 22nd. Finally, ValuEngine lowered Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, October 26th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $21.50.

Vanda Pharmaceuticals (VNDA) traded down $0.10 during trading on Tuesday, reaching $12.85. The company’s stock had a trading volume of 340,500 shares, compared to its average volume of 557,914. Vanda Pharmaceuticals has a 1 year low of $11.90 and a 1 year high of $18.99.

A number of institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its position in Vanda Pharmaceuticals by 7.5% in the 2nd quarter. Vanguard Group Inc. now owns 2,680,895 shares of the biopharmaceutical company’s stock valued at $43,698,000 after buying an additional 186,548 shares during the last quarter. Macquarie Group Ltd. increased its position in shares of Vanda Pharmaceuticals by 10.9% during the 3rd quarter. Macquarie Group Ltd. now owns 1,890,085 shares of the biopharmaceutical company’s stock worth $33,833,000 after purchasing an additional 186,526 shares during the last quarter. State Street Corp increased its position in shares of Vanda Pharmaceuticals by 2.9% during the 2nd quarter. State Street Corp now owns 1,618,485 shares of the biopharmaceutical company’s stock worth $26,380,000 after purchasing an additional 46,299 shares during the last quarter. FMR LLC increased its position in shares of Vanda Pharmaceuticals by 60.7% during the 1st quarter. FMR LLC now owns 1,601,171 shares of the biopharmaceutical company’s stock worth $22,416,000 after purchasing an additional 604,900 shares during the last quarter. Finally, Rothschild Asset Management Inc. acquired a new position in shares of Vanda Pharmaceuticals during the 3rd quarter worth approximately $23,491,000. 87.28% of the stock is currently owned by institutional investors and hedge funds.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Earnings History and Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.